<code id='E1349401DE'></code><style id='E1349401DE'></style>
    • <acronym id='E1349401DE'></acronym>
      <center id='E1349401DE'><center id='E1349401DE'><tfoot id='E1349401DE'></tfoot></center><abbr id='E1349401DE'><dir id='E1349401DE'><tfoot id='E1349401DE'></tfoot><noframes id='E1349401DE'>

    • <optgroup id='E1349401DE'><strike id='E1349401DE'><sup id='E1349401DE'></sup></strike><code id='E1349401DE'></code></optgroup>
        1. <b id='E1349401DE'><label id='E1349401DE'><select id='E1349401DE'><dt id='E1349401DE'><span id='E1349401DE'></span></dt></select></label></b><u id='E1349401DE'></u>
          <i id='E1349401DE'><strike id='E1349401DE'><tt id='E1349401DE'><pre id='E1349401DE'></pre></tt></strike></i>

          hotspot

          hotspot

          author:hotspot    Page View:31363
          Sen. Ron Wyden, D-Ore., left, and Sen. Mike Crapo, R-Idaho, right, walk on Capitol Hill. -- health policy coverage from STAT
          Sen. Ron Wyden, D-Ore., left, and Sen. Mike Crapo, R-Idaho, right, walk on Capitol Hill in 2021. Susan Walsh/AP

          WASHINGTON — One of the top health care committees in the Senate is assembling ideas for bipartisan legislation to address drug shortages, three Senate aides and three lobbyists told STAT.

          The talks, led by Senate Finance Chair Ron Wyden (D-Ore.) and ranking member Mike Crapo (R-Idaho) are in the early days, but they could move the debate over drug shortage reforms into a new phase. The committee has jurisdiction over Medicare and Medicaid payment policies for hospitals. Other committees that have tried tackling the issue have jurisdiction mostly over the Food and Drug Administration.

          advertisement

          The panel is tentatively aiming to hold a hearing on the issue in November, the sources said. The panel has also started accepting input from outside stakeholders, one lobbyist said.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          Drug repurposing or repositioning? The language matters
          Drug repurposing or repositioning? The language matters

          AdobeFindinganewmedicineisnevereasy.Butdevelopingtreatmentsforpatientswithrarediseases—conditionstha

          read more
          ASCO 2024: 'Reassuring' Corbus data on ADC bladder cancer drug
          ASCO 2024: 'Reassuring' Corbus data on ADC bladder cancer drug

          ADAMFEUERSTEIN/STATCHICAGO—CorbusPharmaceuticalsisthesecondbest-performingbiotechstockthisyear,thank

          read more
          Duchenne breakthrough therapy leaves behind pioneering families
          Duchenne breakthrough therapy leaves behind pioneering families

          DuchennemusculardystrophyDr.EdwinP.Ewing,Jr./CDCPatFurlongwassittinginherhomeofficeinMiddletown,Ohio

          read more

          Readout LOUD podcast: How biotech is using artificial intelligence

          HasAIreallysolvedbiology?Whatcanmachinesteachusaboutmedicine?Andwhat’sadigitaltwin?Wecoverallthatand